| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 3 | +33.33% | +4.11% | -0.19% | +4.30% | +5.46% | — |
| 14d | 3 | +33.33% | +3.33% | -0.86% | +4.19% | +11.76% | — |
| 30d | 3 | +100.00% | -8.37% | -0.43% | -7.94% | -0.71% | — |
| 60d | 3 | +33.33% | +104.56% | -2.53% | +107.09% | +168.59% | — |
| 90d | 3 | +33.33% | +142.83% | -6.00% | +148.83% | +219.14% | — |
| 180d | 3(1 pending) | +50.00% | +144.57% | +6.71% | +137.86% | +137.86% | — |
| 1y | 3(2 pending) | +100.00% | -21.83% | +15.76% | -37.59% | -37.59% | — |
| 2y | 3(3 pending) | — | — | — | — | — | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED | DETAILS |
|---|---|---|---|---|---|---|---|---|
| ANTX AN2 THERAPEUTICS, INC. | SALE Chief Development Officer | 41,665 | — | — | 0 | Mar 19, 2026 | Mar 23, 2026 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | SALE Chief Development Officer | 57,950 | — | — | 0 | Mar 19, 2026 | Mar 23, 2026 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | SALE Chief Development Officer | 66,000 | — | — | 0 | Mar 19, 2026 | Mar 23, 2026 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 66,000 | — | — | 66,000 | Mar 19, 2026 | Mar 23, 2026 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 57,950 | — | — | 57,950 | Mar 19, 2026 | Mar 23, 2026 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 41,665 | — | — | 41,665 | Mar 19, 2026 | Mar 23, 2026 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 77,000 | — | — | 77,000 | Feb 20, 2026 | Feb 23, 2026 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 38,000 | — | — | 118,823 | Feb 20, 2026 | Feb 23, 2026 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | SALE Chief Development Officer | 5,956 | $1.01 | $6.0K | 75,823 | Jan 6, 2026 | Jan 7, 2026 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | SALE Chief Development Officer | 3,295 | $1.00 | $3.3K | 81,779 | Jan 5, 2026 | Jan 7, 2026 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 50,250 | — | — | 80,074 | Feb 26, 2025 | Feb 28, 2025 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 100,500 | — | — | 100,500 | Feb 26, 2025 | Feb 28, 2025 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | SALE Chief Development Officer | 2,957 | $1.34 | $4.0K | 29,824 | Jan 3, 2025 | Jan 7, 2025 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 27,500 | — | — | 28,235 | Mar 15, 2024 | Mar 29, 2024 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 55,000 | — | — | 55,000 | Mar 15, 2024 | Mar 18, 2024 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 27,500 | — | — | 28,235 | Mar 15, 2024 | Mar 18, 2024 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 57,950 | — | — | 57,950 | Feb 15, 2023 | Feb 17, 2023 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 66,000 | — | — | 66,000 | May 12, 2022 | May 16, 2022 ↗ | View → |